This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

June 14-16, 2022
Intercontinental Mark Hopkins HotelSan Francisco, California
Menu
Next Generation CAR & T Cell Therapies 2021 Agendakeyboard_arrow_right

Next Generation CAR & T Cell Therapies 2021 Agenda

keyboard_arrow_leftSearch & Filter
search

Next Generation CAR & T Cell Therapies 2021 Agenda

search
Next Generation CAR & T Cell Therapies 2021 Agenda 9:50am - 10:00am10 mins
CONFERENCE DAY ONE - June 22nd
Opening Remarks from Sarah Lintern, Conference Director
    Next Generation CAR & T Cell Therapies 2021 Agenda 9:50am - 10:00am10 mins
    CONFERENCE DAY TWO - June 23rd
    Conference Opening and Welcome
    • Paul Lammers - President & CEO, Triumvira Immunologics
    Next Generation CAR & T Cell Therapies 2021 Agenda 9:50am - 10:00am10 mins
    CONFERENCE THREE - June 24th
    Conference Opening and Welcome
    • Paul Rennert - President & CSO, Aleta BioTherapeutics
    Next Generation CAR & T Cell Therapies 2021 Agenda 10:05am - 10:25am20 mins
    CONFERENCE DAY ONE - June 22nd
    Preclinical CAR T Discovery Candidate Selection for Targets such as CD70 Or DLL3
    • Siler Panowski - Director of Biology, Solid Tumors, Allogene, USA
    Next Generation CAR & T Cell Therapies 2021 Agenda 10:05am - 10:25am20 mins
    CONFERENCE DAY TWO - June 23rd
    Harnessing of Blood Derived Gamma Delta T Cells for Cancer Immunotherapy
    • John Maher - CSO, Leucid Bio, Clinical Senior Lecturer in Immunology, Kings College London
    Next Generation CAR & T Cell Therapies 2021 Agenda 10:05am - 10:25am20 mins
    CONFERENCE THREE - June 24th
    Translational Lessons from Pivotal Axi-Cel Trial (ZUMA-1): Implications for Safety, Efficacy and Next Generation Products
    • Simone Filosto - Principal Scientist I, Cell Biology, Kite Pharma
    Next Generation CAR & T Cell Therapies 2021 Agenda 10:30am - 10:50am20 mins
    CONFERENCE DAY ONE - June 22nd
    Creating a Feedback Loop Between Clinical Trials and Translational Science for Product Improvement
    • Mya Thu - CEO & Co-Founder, VisiCELL Medical, USA
    • Gilbert Fruhwirth - Senior Lecturer in Imaging Biology, King’s College London, UK
    Next Generation CAR & T Cell Therapies 2021 Agenda 10:30am - 10:50am20 mins
    CONFERENCE DAY TWO - June 23rd
    Clinical Development with Two Distinct Proprietary and Unique Non-Gene Edited Allogeneic Technology Approaches
    • Frédéric F. Lehmann - VP Clinical and Medical Affairs, Celyad Oncology, Belgium
    Next Generation CAR & T Cell Therapies 2021 Agenda 10:30am - 10:50am20 mins
    CONFERENCE THREE - June 24th
    Contextual Secretion of Nanoscale, Antigen-Dependent IL-12 By CAR T Cells for Cancer Treatment
    • Zhifen Yang - Associate Director, Refuge Biotech
    Next Generation CAR & T Cell Therapies 2021 Agenda 10:55am - 11:15am20 mins
    CONFERENCE DAY ONE - June 22nd
    CAR NK Cells: The future of cancer immunotherapy
    • Rafet Basar - Assistant Professor, MD Anderson Cancer Center, USA
    Next Generation CAR & T Cell Therapies 2021 Agenda 10:55am - 11:35am40 mins
    CONFERENCE DAY TWO - June 23rd
    PANEL: Next Generation CAR Strategies – Allo, NK and Macrophages for Treating Multiple Patients
    • John Tomtishen - Director of Manufacturing, Technical Operations, Legend Biotech Co., USA
    • John Maher - CSO, Leucid Bio, Clinical Senior Lecturer in Immunology, Kings College London
    • Frédéric F. Lehmann - VP Clinical and Medical Affairs, Celyad Oncology, Belgium
    Next Generation CAR & T Cell Therapies 2021 Agenda 10:55am - 11:15am20 mins
    CONFERENCE THREE - June 24th
    Speaker Q&A
    • Simone Filosto - Principal Scientist I, Cell Biology, Kite Pharma
    • Zhifen Yang - Associate Director, Refuge Biotech
    Next Generation CAR & T Cell Therapies 2021 Agenda 11:15am - 11:40am25 mins
    CONFERENCE THREE - June 24th
    Morning Coffee and Networking
      Next Generation CAR & T Cell Therapies 2021 Agenda 11:20am - 11:40am20 mins
      CONFERENCE DAY ONE - June 22nd
      Speaker Q&A
      • Siler Panowski - Director of Biology, Solid Tumors, Allogene, USA
      • Mya Thu - CEO & Co-Founder, VisiCELL Medical, USA
      • Gilbert Fruhwirth - Senior Lecturer in Imaging Biology, King’s College London, UK
      Next Generation CAR & T Cell Therapies 2021 Agenda 11:35am - 12:00pm25 mins
      CONFERENCE DAY TWO - June 23rd
      Morning Coffee and Networking
        Next Generation CAR & T Cell Therapies 2021 Agenda 11:40am - 12:00pm20 mins
        CONFERENCE DAY ONE - June 22nd
        Morning Coffee and Networking
          Next Generation CAR & T Cell Therapies 2021 Agenda 11:40am - 12:00pm20 mins
          CONFERENCE THREE - June 24th
          Fusion Proteins to Bridge CAR19 T Cell and Tumor Cells
          • Paul Rennert - President & CSO, Aleta BioTherapeutics
          Next Generation CAR & T Cell Therapies 2021 Agenda 12:00pm - 12:20pm20 mins
          CONFERENCE DAY ONE - June 22nd
          In vivo engineering of CAR-T cells: A promising new approach to cancer immunotherapy
          • Shon Green - Senior Director, Translational Sciences, Umoja Biopharma
          Next Generation CAR & T Cell Therapies 2021 Agenda 12:00pm - 12:20pm20 mins
          CONFERENCE DAY TWO - June 23rd
          Driving lupus out with CARs
          • Marko Radic - Associate Professor, Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center
          Next Generation CAR & T Cell Therapies 2021 Agenda 12:05pm - 12:25pm20 mins
          CONFERENCE THREE - June 24th
          DAP10/12 co-stimulation/Signaling Domains & HuLym-1 CAR T-cells Targeting HLA-DR Expressed by Lymphomas and Most Solid Tumors
          • Alan Epstein - Professor of Pathology, Keck School of Medicine of USC, USA
          Next Generation CAR & T Cell Therapies 2021 Agenda 12:25pm - 12:45pm20 mins
          CONFERENCE DAY ONE - June 22nd
          CAR-T therapy for solid tumors: The Road Ahead
          • Shipra Das - Team Leader Immuno-Oncology, Cellectis
          Next Generation CAR & T Cell Therapies 2021 Agenda 12:25pm - 12:45pm20 mins
          CONFERENCE DAY TWO - June 23rd
          Clinical Case Study – Novel CARs & TCRs
          • Paul Lammers - President & CEO, Triumvira Immunologics
          Next Generation CAR & T Cell Therapies 2021 Agenda 12:30pm - 12:50pm20 mins
          CONFERENCE THREE - June 24th
          Speaker Q&A
          • Paul Rennert - President & CSO, Aleta BioTherapeutics
          • Alan Epstein - Professor of Pathology, Keck School of Medicine of USC, USA
          Next Generation CAR & T Cell Therapies 2021 Agenda 12:45pm - 1:05pm20 mins
          CONFERENCE DAY ONE - June 22nd
          Speaker Q&A
          • Shon Green - Senior Director, Translational Sciences, Umoja Biopharma
          • Shipra Das - Team Leader Immuno-Oncology, Cellectis
          Next Generation CAR & T Cell Therapies 2021 Agenda 12:50pm - 1:10pm20 mins
          CONFERENCE DAY TWO - June 23rd
          Production of Superior RNA CAR T Cells using a Novel Lipid Nanoparticle Delivery Platform
          • Samuel Clarke - Director R&D, Reagents, Precision NanoSystems Inc., Canada
          Next Generation CAR & T Cell Therapies 2021 Agenda 12:50pm - 1:35pm45 mins
          CONFERENCE THREE - June 24th
          Sponsored Luncheon Presentations
            Next Generation CAR & T Cell Therapies 2021 Agenda 1:05pm - 2:05pm60 mins
            CONFERENCE DAY ONE - June 22nd
            Sponsored Luncheon Presentations
              Next Generation CAR & T Cell Therapies 2021 Agenda 1:10pm - 1:30pm20 mins
              CONFERENCE DAY TWO - June 23rd
              Speaker Q&A
              • Marko Radic - Associate Professor, Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center
              • Paul Lammers - President & CEO, Triumvira Immunologics
              Next Generation CAR & T Cell Therapies 2021 Agenda 1:30pm - 2:15pm45 mins
              CONFERENCE DAY TWO - June 23rd
              Sponsored Luncheon Presentations
                Next Generation CAR & T Cell Therapies 2021 Agenda 1:35pm - 1:55pm20 mins
                CONFERENCE THREE - June 24th
                Centralized vs. Decentralized Patient Treatment Approaches
                • Allison Matthews - Senior Service Designer, Innovation and Design, Mayo Clinic
                Next Generation CAR & T Cell Therapies 2021 Agenda 1:55pm - 2:00pm5 mins
                CONFERENCE THREE - June 24th
                End of Day Three
                  Next Generation CAR & T Cell Therapies 2021 Agenda 2:05pm - 2:25pm20 mins
                  CONFERENCE DAY ONE - June 22nd
                  Switchable CAR-T for Solid Tumours
                  • Travis Young - VP, Biologics, Calibr at Scripps Research, USA
                  Next Generation CAR & T Cell Therapies 2021 Agenda 2:15pm - 2:35pm20 mins
                  CONFERENCE DAY TWO - June 23rd
                  CAR-M: A new frontier for cell therapy
                  • Michael Klichinsky - Co-Founder, Carisma Therapeutics
                  Next Generation CAR & T Cell Therapies 2021 Agenda 2:30pm - 2:50pm20 mins
                  CONFERENCE DAY ONE - June 22nd
                  3T Case Study - Identification of Novel Targets for the Treatment of Solid Tumours in Broad Patient Populations
                  • Hanspeter Gerber - CSO & SVP, 3T Biosciences
                  Next Generation CAR & T Cell Therapies 2021 Agenda 2:40pm - 3:00pm20 mins
                  CONFERENCE DAY TWO - June 23rd
                  Predictive Biomarkers of Response and Toxicity to Anti-CD19 CAR T Cell Therapy
                  • Rhine Shen - Principal Scientist, Kite, a Gilead Company, USA
                  Next Generation CAR & T Cell Therapies 2021 Agenda 2:55pm - 3:15pm20 mins
                  CONFERENCE DAY ONE - June 22nd
                  Speaker Q&A
                  • Travis Young - VP, Biologics, Calibr at Scripps Research, USA
                  • Blake Aftab - Vice President, Research, Atara Biotherapeutics
                  • Hanspeter Gerber - CSO & SVP, 3T Biosciences
                  Next Generation CAR & T Cell Therapies 2021 Agenda 3:05pm - 3:25pm20 mins
                  CONFERENCE DAY TWO - June 23rd
                  CRISPR Screens for Finding New or Selecting T Cell Edits for Different Solid Tumours
                  • Birgit Schultes - Vice President, Immunology (Cell Therapies), Intellia Therapeutics, USA
                  Next Generation CAR & T Cell Therapies 2021 Agenda 3:15pm - 3:20pm5 mins
                  CONFERENCE DAY ONE - June 22nd
                  End of Day One
                    Next Generation CAR & T Cell Therapies 2021 Agenda 3:30pm - 3:50pm20 mins
                    CONFERENCE DAY TWO - June 23rd
                    On the Importance of Monitoring Both Transfection & Transduction Efficiencies in Cell Therapy Development
                    • Derek C. Lenz - Senior Marketing Manager, Biopharma Market, Beckman Coulter, Life Sciences, USA
                    Next Generation CAR & T Cell Therapies 2021 Agenda 3:50pm - 4:10pm20 mins
                    CONFERENCE DAY TWO - June 23rd
                    Speaker Q&A
                    • Michael Klichinsky - Co-Founder, Carisma Therapeutics
                    • Rhine Shen - Principal Scientist, Kite, a Gilead Company, USA
                    • Birgit Schultes - Vice President, Immunology (Cell Therapies), Intellia Therapeutics, USA
                    Next Generation CAR & T Cell Therapies 2021 Agenda 4:10pm - 4:15pm5 mins
                    CONFERENCE DAY TWO - June 23rd
                    End of Day Two
                      Filter
                      Streams
                      Formats
                      Choose Day